| Print
Amgen (AMGN)
Common SharesNot yet a customer?
Low cost dealing from £1.50Choose from our range of SIPP, ISA and Dealing accounts
Find out moreThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introducedits first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgenalso has a growing biosimilar portfolio.
Address
One Amgen Center Drive
Thousand Oaks
CA
USA
91320-1799
Telephone
+1 805 4471060
Forecast key dates
| Name | Key Date |
|---|---|
| Amgen Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-05T13:30:00 |
| Amgen Inc Second Quarter Earnings Results for 2026 | 2026-08-05T00:00:00 |
| Amgen Inc Annual General Meeting for 2026 | 2026-05-22T11:00:00 |
| Amgen Inc First Quarter Earnings Conference Call for 2026 | 2026-05-01T13:30:00 |
| Amgen Inc First Quarter Earnings Results for 2026 | 2026-05-01T00:00:00 |
| Amgen Inc Annual Report for 2025 | 2026-02-13T00:00:00 |
| Amgen Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-02-04T16:30:00 |
| Amgen Inc Fourth Quarter Earnings Results for 2025 | 2026-02-04T00:00:00 |
| Amgen Inc Third Quarter Earnings Conference Call for 2025 | 2025-11-04T13:30:00 |
| Amgen Inc Third Quarter Earnings Result for 2025 | 2025-11-04T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.